Citation Impact
Citing Papers
Blockade of EGFR and ErbB2 by the Novel Dual EGFR and ErbB2 Tyrosine Kinase Inhibitor GW572016 Sensitizes Human Colon Carcinoma GEO Cells to Apoptosis
2006
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
2008 Standout
Factors Associated With Severe Late Toxicity After Concurrent Chemoradiation for Locally Advanced Head and Neck Cancer: An RTOG Analysis
2008 Standout
Lysophosphatidic acid-induced squamous cell carcinoma cell proliferation and motility involves epidermal growth factor receptor signal transactivation.
2002
ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.
2003
Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment.
2003
Astrocytes: biology and pathology
2009 Standout
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
2006 Standout
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs): Simple drugs with a complex mechanism of action?
2002
Study of the Biologic Effects of Lapatinib, a Reversible Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, on Tumor Growth and Survival Pathways in Patients With Advanced Malignancies
2005
ERBB receptors and cancer: the complexity of targeted inhibitors
2005 Standout
Endogenous human microRNAs that suppress breast cancer metastasis
2008 StandoutNature
EGFR Antagonists in Cancer Treatment
2008 Standout
Expression of epidermal growth factor receptor (EGFR) and downstream-activated peptides in surgically excised non-small-cell lung cancer (NSCLC)
2003
ErbB-targeted therapeutic approaches in human cancer
2003
ZD1839: targeting the epidermal growth factor receptor in cancer therapy
2002
AKT/PKB Signaling: Navigating Downstream
2007 Standout
Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial
2003 Standout
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer
2003 Standout
Epidermal growth factor receptor mutations in lung cancer
2007 Standout
PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization
2002
Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment
2016 Standout
Epidermal Growth Factor Receptor Targeting in Cancer
2006
Head and neck cancer
2008 Standout
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
2006 Standout
Malignant astrocytic glioma: genetics, biology, and paths to treatment
2007 Standout
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
2004 Standout
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance
2006 Standout
Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery
2005 Standout
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
2005 Standout
Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs
2003
Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa®, ZD1839) in chemotherapy‐resistant non‐small cell lung cancer
2004
Discovery of curcumin, a component of golden spice, and its miraculous biological activities
2011 Standout
Inflammation and Colon Cancer
2010 Standout
Metastasis suppressors alter the signal transduction of cancer cells
2003
Mechanism of Action of Anti-Her2 Monoclonal Antibodies: Scientific Update on Trastuzumab and 2c4
2003
Targeting RAS signalling pathways in cancer therapy
2003 Standout
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
2005 Standout
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
2007 Standout
Emerging Biological Principles of Metastasis
2017 Standout
Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers
2005 Standout
PI3K/Akt signalling pathway and cancer
2003 Standout
Developing Inhibitors of the Epidermal Growth Factor Receptor for Cancer Treatment
2003
Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx
2001
Epidermal growth factor receptor tyrosine kinase inhibitors
2002
Tumor metastasis: mechanistic insights and clinical challenges
2006 Standout
Akt signalling in health and disease
2011 Standout
TACE is required for the activation of the EGFR by TGF-α in tumors
2003
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
2005 Standout
Hepatocellular carcinoma pathogenesis: from genes to environment
2006 Standout
Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies
2006 Standout
Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma
2004
Epidermal growth factor receptor (EGFR) signaling in cancer
2005 Standout
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
2008 Standout
Guidelines for the diagnosis and management of individuals with neurofibromatosis 1
2006 Standout
Oxidative Stress: Harms and Benefits for Human Health
2017 Standout
Trastuzumab-Induced Hepatotoxicity: A Case Report
2013 Standout
Anemia of Chronic Disease
2005 Standout
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
2004 Standout
PI3K-Akt pathway: Its functions and alterations in human cancer
2004 Standout
HER2/neu Expression in Head and Neck Squamous Cell Carcinoma Patients is not Significantly Elevated
2012
Deacetylated sialic acids modulates immune mediated cytotoxicity via the sialic acid-Siglec pathway
2021 StandoutNobel
BindingDB Entry 50022499: ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.
2025
Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer
2005
Swallowing Function after Chemoradiation for Advanced Stage Oropharyngeal Cancer
2006
Stress and Radiation-Induced Activation of Multiple Intracellular Signaling Pathways1
2003
Inhibition of pancreatic and lung adenocarcinoma cell survival by curcumin is associated with increased apoptosis, down-regulation of COX-2 and EGFR and inhibition of Erk1/2 activity.
2007
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
2013 Standout
Proteomic Analysis Reveals Hyperactivation of the Mammalian Target of Rapamycin Pathway in Neurofibromatosis 1–Associated Human and Mouse Brain Tumors
2005
The TSC1–TSC2 complex: a molecular switchboard controlling cell growth
2008 Standout
Phase II Trial of Gefitinib 250 mg Daily in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
2005
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
2008 Standout
Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.
2003
Phase II Trial of ZD1839 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
2003
Phase I Study of the Humanized Antiepidermal Growth Factor Receptor Monoclonal Antibody EMD72000 in Patients With Advanced Solid Tumors That Express the Epidermal Growth Factor Receptor
2003
Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer
2005 Standout
Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer
2003
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types
2002
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
2004 Standout
Works of G. Raspall being referenced
Preoperative induction chemotherapy followed by concurrent chemoradiotherapy in advanced carcinoma of the oral cavity and oropharynx
2000
Preoperative Simultaneous Chemoradiotherapy in Locally Advanced Cancer of the Oral Cavity and Oropharynx
1997
Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments.
2001